

**Report to the CDC Board of
Scientific Counselors,
Office of Infectious Diseases**

Antimicrobial Resistance Working Group

Dr. Robert A. Weinstein, Chair

August 19, 2014



Centers for Disease Control and Prevention
Office of Infectious Diseases

In-Person Meeting

May 6, 2014

AGENDA

- **CDC Presentations**
- **Discussion**
 - **Lab and diagnostics**
 - **Antibiotic Use**
 - **Prevention**
- **Working Plan (2014-2016)**



CDC Presentations

- ❑ **CRE Prevention Framework Development – Alex Kallen**
- ❑ **Update on Stewardship and Judicious Use Activities – Scott Fridkin**
- ❑ **CDC Future Plans: AR and the President's 2015 Budget – Jean Patel**
- ❑ **Drug-resistant Gonorrhea – Bob Kirkaldy**



Workplan (2014-2016)

- **The Working Group will focus its activities in three general areas:**
 - **Laboratory Capacity / Surveillance**
 - **Improving Antibiotic Use / Stewardship**
 - **Promoting Evidence-based Prevention Practices**
- **Each Focus Area will have conference calls on a monthly or bi-monthly basis**
 - **Calls are open to all members, though some have indicated a preference for greater involvement in some focus area work than others**



Focus Area Conference Calls

- **Laboratory Focus Area: June 11 and July 31**
- **Antibiotic Use Focus Area: June 30**
- **AR Prevention Focus Area: July 1**



Laboratory Focus Area

- ❑ **The purpose: Identify gaps in laboratory testing for antimicrobial resistance (i.e., what data are usually generated in hospital labs and what data do we need for prevention and control of antimicrobial resistance)**
- ❑ **The WG is discussing testing gaps and will consider:**
 - Is the testing gap described important and will the need for testing increase
 - How can the testing gap be filled
 - What are key drivers and barriers to filling the testing gap



Testing Gaps Under Consideration

- ❑ **Methods to identify patients colonized with MDRO pathogens like CRE**
- ❑ **Molecular typing of MDRO pathogens to identify outbreaks and to understand transmission dynamics**
- ❑ **Methods to detect resistance mechanisms for MDRO pathogens such as CRE**
- ❑ **Testing of extreme- or pan-drug resistant (XDR, PDR) pathogens for susceptibility to agents not available on antimicrobial susceptibility testing devices (e.g., new drugs or older drugs like polymyxin B and fosfomycin).**



Antibiotic Use Focus Area

- ❑ **Help promote adoption of CDC-proposed NQF stewardship measure**
- ❑ **Identify knowledge gaps in our understanding of how best to implement practices and policies to improve AU, especially for outpatient and LTC**
- ❑ **Identify “easy wins” to demonstrate success of interventions**
- ❑ **Recommend strategies for targeting communication messages to increase awareness and acceptance of stewardship**
- ❑ **Promote the use of reimbursement/incentive models to help change prescribing behavior**



AR Prevention Focus Area

- ❑ **Help develop criteria that could be used to identify the most effective prevention strategies—those that should be recommended for broad adoption—in different settings (acute care, LTC, outpatient)**
- ❑ **Identify adaptations that may be needed to broaden uptake of regional prevention strategies (e.g., Chicago REALM, IL XDRO registry) in other areas**
- ❑ **Examine potential utility of non-antibiotic prevention strategies (e.g., restoring gut microbiota, vaccines)**
- ❑ **Examine pros and cons and potential role of notifiable disease reporting and public reporting of selected AR infections**



Future Meetings and Conference Calls

- **ARWG Conference Call: August 13**
- **Focus Area Conference Calls: TBD - September**
- **ARWG In-person Meeting: December 9**

